PhaseBio Diabetes Program Reaches Inflection Point With Series B Add-On
This article was originally published in The Pink Sheet Daily
Executive Summary
Privately held biotech announces an additional $23 million raise from existing investors to finance a head-to-head Phase IIb trial for its GLP-1 analogue against Victoza.
You may also be interested in...
With Bydureon’s U.S. Approval, Amylin Extends Exenatide Franchise
Twice delayed by “complete response” letters, the drug’s approval gives Amylin a once-weekly GLP-1 analog, the longest-acting drug in its class.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.